explore -WSS

explore

author：leisure time 2025-09-28 00:48:15 - browse：656

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： What causes osteoarthritis? Researchers study link to brain protein

WSS

Judge orders hearing on Trump's motion to disqualify Fulton County DA

Snowpack in the West is melting rapidly. Where will all that extra water go?

TikTok, Instagram influencers need more rules for drug ads

FDA sets aggressive timeline for overhauling inspection procedures

Many immigrants are left out of maternal health programs

Cardiologists urge adding sexual orientation, gender identity to health records

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Jerome Adams on the need for new antivirals for Covid

House GOP plan to stem drug shortages differs from Democrats’

Psychedelics group wrestles with new pharma identity

Poland's lawmakers approve a divisive law on Russian influence

Medical records are filled with copy

Europe is fastest

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Dobbs anniversary: the lost opportunity of abortion as health care

Poland's lawmakers approve a divisive law on Russian influence

focus

Poland's lawmakers approve a divisive law on Russian influence

Inaction leaves children at risk from dangerous chemotherapy drug

Putin woos African leaders at a summit in Russia with promises of expanding trade and other ties

The inclusion problem at the heart of rehabilitation research

Microsoft launches AI tool for clinical documentation through Epic

High breast density mammograms need follow

focus

focus

leisure time

explore